On 9 November, researchers from University of Oxford (UK) and the Alzheimer Center Amsterdam (Netherlands) published an article in the journal Alzheimer’s Research Therapy entitled “Prediction of Alzheimer’s disease biomarker status defined by the ‘ATN framework’ among cognitively healthy individuals: results from the EPAD longitudinal cohort study”.
In this paper, authors tested the predictive utility of validated composite risk scores in their association with the Amyloid/Tau/Neurodegeneration (ATN)-defined biomarker group status in a cognitively healthy ageing sample drawn from the EPAD longitudinal cohort study. The main aim was to investigate independent risk factors for Alzheimer’s disease and vascular-related composite risk scores, in relation to prediction of ATN pathology. The sample is drawn from 1,500 adult participants aged over 50 years recruited across 21 European sites from the EPAD study.
The EPAD project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. You can read the open-access article here: http://dx.doi.org/10.1186/s13195-020-00711-5